Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Dynamic insulin algorithm improves glycaemic control in non-critically ill patients
Última actualización 18 de julio de 2026
Key finding
Time to control hyperglycaemia decreased from 8.3 hours to 5.3 hours.
This study evaluated the efficacy of a dynamic algorithm for intravenous insulin therapy compared to a static protocol in non-critically ill patients, finding significant improvements in glycaemic control.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of a dynamic algorithm for intravenous insulin therapy compared to a static protocol in non-critically ill patients, finding significant improvements in glycaemic control.
Clinical relevance
Improving glycaemic control in non-critically ill patients is crucial for preventing complications associated with diabetes. The findings suggest that a dynamic approach to insulin therapy may enhance patient outcomes, reduce hospital stays, and lower the risk of hypoglycaemia, ultimately leading to better management of blood sugar levels in this population.
Keep in mind
Non-randomized design may introduce bias. Sample size and demographic details were not specified. Results may not be generalizable to all patient populations.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Nathanaëlle M, Lise B, Céline L, et al. Efficacy of a dynamic algorithm of intravenous insulin therapy in non-critically ill patients. PLOS ONE. 2019;14(1):e0211425. doi:10.1371/journal.pone.0211425
Efectos Principales
Time to control hyperglycaemia decreased by 3 hours (from 8.3 to 5.3 hours, p=0.01).
In-target blood glucose measurements increased by 4.8% (from 37.0% to 41.8%, p=0.05).
Recurrence of mild hypoglycaemia decreased by 10.3% (from 20.5% to 10.2%, p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin therapy, Static protocol of insulin infusion and Glucose variability, Hypoglycemia events, Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L, and 3 more.
This study contributes evidence to
Primary intervention
Insulin therapy
Primary outcomes
- Glucose variability
- Hypoglycemia events
- Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
342
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Insulin Therapies and CGM Time in Range
Evidencia relacionada
Relación de evidencia
Insulin Therapies and Hypoglycemia
Guardar evidencia
Relación de evidencia
Insulin Therapies and Glucose Variability
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerPercentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Insulin therapy → Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Insulin therapy → Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerRecurrence of mild hypoglycaemia
Insulin therapy → Recurrence of mild hypoglycaemia
Insulin therapy → Recurrence of mild hypoglycaemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTime to glycemic target
Insulin therapy → Time to glycemic target
Insulin therapy → Time to glycemic target
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerTime to achieve glycaemic control with static protocol
Static protocol of insulin infusion → Time to achieve glycaemic control with static protocol
Static protocol of insulin infusion → Time to achieve glycaemic control with static protocol
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Dynamic algorithm reduced time to control hyperglycaemia by 3 hours.
- In-target blood glucose measurements increased by 4.8%.
- Recurrence of mild hypoglycaemia decreased by 10.3%.
A quién se aplica
- Non-critically ill patients requiring insulin therapy.
- Patients with diabetes experiencing hyperglycaemia.
Tener en Cuenta
- The study's non-randomized design limits causal inferences.
- Findings may not apply to critically ill patients.
- Further research is needed to confirm long-term benefits.
Entre Líneas
- Non-randomized design may introduce bias.
- Sample size and demographic details were not specified.
- Results may not be generalizable to all patient populations.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and Hypoglycemia, Insulin Therapies and Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin Therapies → Hypoglycemia
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
Insulin Therapies → Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Hypoglycemia Evidence Hub
All studies measuring Hypoglycemia
2 studies
outcome_hubMeasures Hypoglycemia as a key outcome.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
2 studies
intervention_hubContributes to Insulin Therapies evidence base.
Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L Evidence Hub
All studies measuring Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
2 studies
outcome_hubMeasures Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin therapy and Hypoglycemia events
Intervention: Insulin therapyOutcome: Hypoglycemia events
2 results
All studies on Insulin therapy and Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Intervention: Insulin therapyOutcome: Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
2 results
All studies on Insulin therapy
Intervention: Insulin therapy
2 results
All studies measuring Hypoglycemia events
Outcome: Hypoglycemia events
2 results
All studies measuring Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
Outcome: Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Therapies improve cgm time in range?
Strong Evidence
Insulin Therapies may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Time to glycemic target
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin Therapies affect hypoglycemia?
Strong Evidence
Insulin Therapies may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin Therapies improve glucose variability?
Moderate Evidence
Insulin Therapies appears to improve Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Glucose variability
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Insulin therapy improve percentage of blood glucose measurements within target range of 3.9–7.8 mmol/l?
Moderate Evidence
Insulin therapy appears to improve Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Percentage of blood glucose measurements within target range of 3.9–7.8 mmol/L
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide with Insulin Improves Diabetes Control and Kidney HealthVildagliptin improves glycemic control in type 2 diabetes patients on insulinHybrid Closed-Loop System Reduces Insulin Boluses in Youth with Type 1 DiabetesQCC Model Enhances Diabetes ManagementCloud platform improves algorithm testing for type 1 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.